Stockscreener 앱 받기
71.34
2.93%
2.03
시간 외 거래:
72.56
1.22
+1.71%
전일 마감가:
$69.31
열려 있는:
$69.12
하루 거래량:
1.15M
Relative Volume:
0.71
시가총액:
$7.66B
수익:
$628.56M
순이익/손실:
$141.82M
주가수익비율:
56.62
EPS:
1.26
순현금흐름:
$142.60M
1주 성능:
-3.58%
1개월 성능:
-0.47%
6개월 성능:
+42.77%
1년 성능:
+126.05%
1일 변동 폭
$68.52
$71.57
1주일 범위
$68.52
$75.95
52주 변동 폭
$29.42
$117.33
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
CORT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
71.34 | 7.66B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much TodayCorcept Therapeutics (NASDAQ:CORT) - Benzinga
Corcept reports annual meeting outcomes By Investing.com - Investing.com Canada
Corcept May 2025 slides: Revenue target of $900-950M amid pipeline advances - Investing.com Canada
Corcept Therapeutics director Daniel Swisher sells $155k in stock - Investing.com Australia
Corcept Therapeutics director Daniel Swisher sells $155k in stock By Investing.com - Investing.com Canada
Insider Sell: Swisher Daniel N JR Sells 2,200 Shares of Corcept Therapeutics Inc (CORT) - GuruFocus
Relacorilant delays ovarian cancer disease progression: Trial data - Rare Cancer News
Corcept claims survival benefit in ALS despite missed endpoint - PharmaLive
Mixed Phase II results for Corcept’s dazucorilant - The Pharma Letter
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Purchased by Public Employees Retirement System of Ohio - Defense World
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting - afp.com
Corcept plots future for ALS drug that flunked Phase 2, citing survival analysis - Endpoints News
Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study - Benzinga
Corcept's mid-stage ALS study fails (CORT:NASDAQ) - Seeking Alpha
Corcept Presents Results from Phase 2 Study of Dazucorilant in P - GuruFocus
Corcept Therapeutics Says Its ALS Drug Candidate Fails to Meet Primary Goal - marketscreener.com
Corcept Therapeutics (CORT) Reports Promising Survival Data in A - GuruFocus
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting | CORT Stock News - GuruFocus
Corcept Therapeutics (CORT) Reports Promising Survival Data in ALS Study | CORT Stock News - GuruFocus
Corcept therapeutics officer Joseph Lyon sells shares worth $390,218 By Investing.com - Investing.com Canada
Corcept therapeutics officer Joseph Lyon sells shares worth $390,218 - Investing.com Australia
Corcept (CORT) Down 1.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
H.C. Wainwright Reaffirms Corcept Therapeutics Incorporated (CORT)’s $145 Price Target, Maintains Buy Rating - Insider Monkey
ASCO 2025: Corcept Therapeutics’ relacorilant emerges as promising agent in recurrent ovarian cancer - Yahoo Finance
Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday - Yahoo
Corcept Therapeutics (NasdaqCM:CORT) Announces Positive Phase 3 Results For Ovarian Cancer Treatment - Yahoo Finance
Relacorilant shows promise for ovarian cancer treatment By Investing.com - Investing.com Nigeria
Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with - GuruFocus
Corcept Therapeutics (CORT) Shows Positive Phase 3 Trial Results for Ovarian Cancer Treatment | CORT Stock News - GuruFocus
Corcept shares rise on positive Phase 3 trial results By Investing.com - Investing.com Nigeria
Corcept shares rise on positive Phase 3 trial results - Investing.com Australia
Relacorilant shows promise for ovarian cancer treatment - Investing.com
Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
Zacks Research Issues Pessimistic Outlook for CORT Earnings - Defense World
Here's How Much $1000 Invested In Corcept Therapeutics 5 Years Ago Would Be Worth Today - Benzinga
Zacks Research Has Negative Outlook for CORT Q2 Earnings - Defense World
Equities Analysts Offer Predictions for CORT Q1 Earnings - Defense World
Bank of America Corp DE Cuts Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Nuveen Asset Management LLC - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock Holdings Lessened by Cetera Investment Advisers - Defense World
Abortion Drugs Market Deep Research and Growth in Future Scope - openPR.com
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT) - FinancialContent
Director, Oncology Patient Support OperationsRedwood CityCorcept Therapeutics - Ladders
Deutsche Bank AG Buys 24,051 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed - Yahoo Finance
Critical Review: Kaya (OTCMKTS:KAYS) vs. Corcept Therapeutics (NASDAQ:CORT) - Defense World
Cushing's Disease Market Poised for Significant Growth Across the 7MM During the Study Period (2020-2034) with Rising Awareness and Diagnostic Improvements | DelveInsight - Yahoo Finance
Cushing's Syndrome Market Growth Drivers and Industry Insights - openPR.com
Corcept Therapeutics (NASDAQ:CORT) Downgraded to “Hold” Rating by StockNews.com - Defense World
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Is Posting Promising Earnings But The Good News Doesn’t Stop There - Yahoo Finance
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):